Neuroimaging, biomarkers, and management of dementia with Lewy bodies

Frontiers in Neurology

Volumn 4 OCT, Issue , 2013, Pages

  Hanagasi, Hasmet A ^a   Bilgiç, Basar ^a   Emre, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Biomarkers; Dementia; Lewy bodies; Lewy body disease; Magnetic resonance imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; ALPHA SYNUCLEIN; AMANTADINE; AMYLOID; AMYLOID 38; AMYLOID BETA PROTEIN[1-40]; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; FLUORODEOXYGLUCOSE; LEVODOPA; MELATONIN; MEMANTINE; METHYLPHENIDATE; MIDODRINE; MODAFINIL; MONOAMINE OXIDASE B INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APATHY; ARTICLE; BED REST; BEDTIME DOSAGE; BEHAVIOR; BLOOD PRESSURE MONITORING; CEREBROSPINAL FLUID; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPRESSION STOCKING; DAYTIME SOMNOLENCE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; DIFFUSION; DIFFUSION TENSOR IMAGING; DRUG CONTRAINDICATION; DRUG TOLERABILITY; ELECTROMYOGRAPHY; EXCESSIVE DAYTIME SLEEPINESS; EXCESSIVE DAYTIME SOMNOLENCE; FRACTIONAL ANISOTROPY; HUMAN; HYDRATION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARASOMNIA; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALT INTAKE; SCINTIGRAPHY; SCORING SYSTEM; SEDATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP DISORDERED BREATHING; SOMNOLENCE; SPECTROSCOPY; STANDING; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TREMOR; VISUAL HALLUCINATION; VOMITING;

EID: 84885355216     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00151     Document Type: Article

References (34)

1. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain (2009) 132:195-203. doi: 10.1093/brain/awn298.
2. Sabattoli F, Boccardi M, Galluzzi S, Treves A, Thompson PM, Frisoni GB. Hippocampal shape differences in dementia with Lewy bodies. Neuroimage (2008) 41:699-705. doi:10.1016/j.neuroimage.2008.02.060.
3. Burton EJ, Mukaetova-Ladinska EB, Perry RH, Jaros E, Barber R, O'Brien JT. Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol Aging (2012) 33:1228-36. doi:10.1016/j.neurobiolaging.2010.12.015.
4. Kantarci K, Ferman TJ, Boeve BF, Weigand SD, Przybelski S, Vemuri P, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology (2012) 79:553-60. doi:10.1212/WNL.0b013e31826357a5.
5. O'Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology (2001) 56:1386-8. doi:10.1212/WNL.56.10.1386.
6. Bozzali M, Falini A, Cercignani M, Baglio F, Farina E, Alberoni M, et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain (2005) 128:1595-604. doi:10.1093/brain/awh493.
7. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage (2003) 20:1309-19. doi:10.1016/S1053-8119(03)00364-1.
8. Watson R, Blamire AM, Colloby SJ, Wood JS, Barber R, He J, et al. Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology (2012) 79:906-14. doi:10.1212/WNL.0b013e318266fc51.
9. Kenny ER, Blamire AM, Firbank MJ, O'Brien JT. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease. Brain (2012) 135:569-81. doi:10.1093/brain/awr327.
10. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology (2001) 56:643-9. doi:10.1212/WNL.56.5.643.
11. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology (1996) 47:462-6. doi:10.1212/WNL.47.2.462.
12. Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology (2000) 55:1575-7. doi:10.1212/WNL.55.10.1575.
13. O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry (2009) 194:34-9. doi:10.1192/bjp.bp.108.052050.
14. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 6:305-13. doi:10.1016/S1474-4422(07)70057-1.
15. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2001) 71:583-8. doi:10.1136/jnnp.71.5.583.
16. Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T, et al. Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord (2011) 17:395-7. doi:10.1016/j.parkreldis.2011.02.001.
17. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord (2010) 25:2516-23. doi:10.1002/mds.23393.
18. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain (2008) 131:690-705. doi:10.1093/brain/awm322.
19. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 213:315-25. doi:10.1016/j.expneurol.2008.06.004.
20. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2009) 450:332-5. doi:10.1016/j.neulet.2008.11.015.
21. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki H-W, Sparbier K, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 129:1177-87. doi:10.1093/brain/awl063.
22. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry (2008) 64:850-5. doi:10.1016/j.biopsych.2008.02.016.
23. Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, et al. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2011) 82:160-4. doi:10.1136/jnnp.2009.199398.
24. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol (2004) 3:19-28. doi:10.1016/S1474-4422(03)00619-7.
25. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2005) 76:1200-3. doi:10.1136/jnnp.2004.052332.
26. Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, et al. Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord (2010) 16:522-6. doi:10.1016/j.parkreldis.2010.06.004.
27. Postuma RB, Gagnon J-F, Montplaisir JY. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis (2012) 46:553-8. doi:10.1016/j.nbd.2011.10.003.
28. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ (1992) 305:673-8. doi:10.1136/bmj.305.6855.673.
29. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry (2010) 23:574-81. doi:10.1097/YCO.0b013e32833f46c9.
30. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000) 356:2031-6. doi:10.1016/S0140-6736(00)03399-7.
31. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol (2012) 72:41-52. doi:10.1002/ana.23557.
32. Dalfó E, Albasanz JL, Martin M, Ferrer I. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions. Brain Pathol (2004) 14:388-98. doi:10.1111/j.1750-3639.2004.tb00082.x.
33. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2009) 8:613-8. doi:10.1016/S1474-4422(09)70146-2.
34. Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 9:969-77. doi:10.1016/S1474-4422(10)70194-0.